In 2020 will the maker of a new immunotherapy be willing to give up even more of the value of their new hospital administered cancer treatment through statutory price reductions to fund the cost of distributing old and commoditised generic medicines? …
Latest Video
New Stories
-
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 - - Latest News -
Scope of practice review recommends formation of new committee
April 19, 2024 - - Latest News -
The HTA review reference committee members should ask themselves one question
April 18, 2024 - - Latest News -
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News -
Retail leader's surprise at the size of revenue revealed by Chemist Warehouse
April 17, 2024 - - Latest News